0001654954-21-005724.txt : 20210514 0001654954-21-005724.hdr.sgml : 20210514 20210514172551 ACCESSION NUMBER: 0001654954-21-005724 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210514 DATE AS OF CHANGE: 20210514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20791 FILM NUMBER: 21926194 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 4134 BUSINESS PARK DRIVE CITY: AMARILLO STATE: TX ZIP: 79110-4225 BUSINESS PHONE: (806) 376-1741 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 4134 BUSINESS PARK DRIVE CITY: AMARILLO STATE: TX ZIP: 79110-4225 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 10-Q 1 amar_10q.htm QUARTERLY REPORT amar_10q
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
 
 
(Mark One)
 
[] 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
or
 
[ ] 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from____to____ Commission File No. 0-20791
 
AINOS, INC.
(Exact name of registrant as specified in its charter)
 
TEXAS
 
75-1974352
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)
 
8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108
(858) 869-2986
(Address and telephone number, including area code, of registrant's principal executive offices)
 
AMARILLO BIOSCIENCES, INC.
4134 Business Park Drive, Amarillo, TX 79110-4225
(Former name or former address if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [√]Yes [ ]No
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [√]Yes [ ]No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer [ ]
 
Accelerated filer [ ]
Non-accelerated filer [ ]
 
Smaller reporting company [√]
 
 
Emerging growth company [ ]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. D
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) [ ] Yes [√] No
 
142,240,594 shares of common stock, par value $0.01 per share, outstanding as of May 14, 2021

 
 
 
AINOS, INC.
 
INDEX
 
 
 
PAGE NO.
PART I:
FINANCIAL INFORMATION
 
ITEM 1.
Financial Statements
 
 
Balance Sheets– March 31, 2021 and December 31, 2020 (unaudited
3
 
Statements of Operations – Three Months Ended March 31, 2021 and 2020 (unaudited)
4
 
Statements of Stockholders’ Equity (Deficit) – Three Months Ended March 31, 2021 and 2020 (unaudited)
5
 
Condensed Statements of Cash Flows – Three Months Ended March 31, 2021 and 2020 (unaudited)
6
 
Notes to Financial Statements (unaudited)
7
ITEM 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
12
ITEM 3.
Quantitative and Qualitative Disclosures About Market Risk
19
ITEM 4.
Controls and Procedures
19
 
 
 
PART II:
OTHER INFORMATION
 
ITEM 1.
Legal Proceedings
20
ITEM 2.
Unregistered Sales of Equity Securities and Use of Proceeds
24
ITEM 3.
Defaults Upon Senior Securities
24
ITEM 4.
Mine Safety Disclosures
24
ITEM 5.
Other Information
24
ITEM 6.
Exhibits
25
Signatures  
27
 
 
 
 
 
 
 
2
 
 
PART I - FINANCIAL INFORMATION
 
ITEM 1. 
Financial Statements
Ainos, Inc.
Balance Sheets
(Unaudited)
 
 
 
March 31,
2021
 
 
December 31,
2020
 
Assets
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
   Cash and cash equivalents
 $9,377 
 $22,245 
   Inventory
  - 
  3,024 
   Prepaid expense and other current assets
  32,890 
  51,144 
Total current assets
  42,267 
  76,413 
Patents, net
  177,051 
  180,628 
Property and equipment, net
  2,921 
  3,249 
Total assets
 $222,239 
 $260,290 
 
    
    
 
    
    
Liabilities and Stockholders' Equity (Deficit)
    
    
Current liabilities:
    
    
   Accounts payable and accrued expenses
 $348,548 
 $145,567 
   Notes payable – related party
  236,854 
  - 
   Convertible notes payable – related party
  915,016 
  953,001 
Total current liabilities
  1,500,418 
  1,098,568 
Total liabilities
  1,500,418 
  1,098,568 
 
    
    
 
    
    
 
    
    
Stockholders' equity (deficit)
    
    
   Preferred stock, $0.01 par value:
    
    
     Authorized shares - 10,000,000,
    
    
Issued and outstanding shares – 0 at March 31, 2021 and December 31, 2020
  - 
  - 
   Common stock, $0.01 par value:
    
    
     Authorized shares - 100,000,000,
    
    
Issued and outstanding shares – 42,066,172 and 42,066,172 at March 31, 2021 and December 31, 2020, respectively
  420,662 
  420,662 
   Additional paid-in capital
  5,055,420 
  4,961,315 
   Accumulated deficit
  (6,754,261)
  (6,220,255)
Total stockholders’ equity (deficit)
  (1,278,179)
  (838,278)
Total liabilities and stockholders’ equity (deficit)
 $222,239 
 $260,290 
 
See accompanying notes to financial statements.
 
3
 
 
Ainos, Inc.
Statements of Operations
(Unaudited)
 
 
 
Three Months Ended March 31,
 
 
 
2021
 
 
2020
 
Revenues
 $2,121 
 $15,200 
Cost of revenues
  (1,249)
  (10,806)
Gross margin
  872 
  4,394 
 
    
    
Operating expenses:
    
    
  Selling, general and administrative expenses
  522,981 
  380,268 
     Total operating expenses
  522,981 
  380,268 
 
    
    
Operating loss
  (522,109)
  (375,874)
 
    
    
Other income (expense):
    
    
  Interest expense, net
  (11,897)
  (1,005)
Net loss
  (534,006)
  (376,879)
Less: Net Income attributable to non-controlling interests
  - 
  - 
Net loss attributable to common shareholders
 $(534,006)
 $(376,879)
 
    
    
Basic and diluted net loss per average share available to common shareholders
 $(0.01)
 $(0.01)
 
    
    
Weighted average common shares outstanding – basic and diluted
  42,066,172 
  40,516,351 
 
See accompanying notes to financial statements.
 
 
4
 
 
Ainos, Inc.
Statements of Stockholders’ Equity (Deficit)
For the three months ended March 31, 2021 and 2020
(Unaudited)
 
 
 
Preferred Stock
 
 
Common Stock
 
 
Additional Paid in
 
 
 Accumulated
 
 
Total Stockholders'
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
 Amount
 
 
Capital
 
 
 Deficit
 
 
 Equity (Deficit)
 
Balance at December 31, 2019
  - 
 $- 
  40,516,351 
 $405,164 
  4,207,786 
  (4,769,632)
  (156,682)
Warrant expense
  - 
  - 
  - 
  - 
  9,496 
  - 
  9,496 
Option expense
  - 
  - 
  - 
  - 
  90,688 
  - 
  90,688 
Net loss
  - 
  - 
  - 
  - 
  - 
  (376,879)
  (376,879)
Balance at March 31, 2020
  - 
 $- 
  40,516,351 
 $405,164 
  4, 307,970 
  (5,146,511)
  (433,377)
 
    
    
    
    
    
    
    
Balance at December 31, 2020
  - 
 $- 
  42,066,172 
 $420,662 
  4,961,315 
  (6,220,255)
  (838,278)
 
Warrant expense
  - 
  - 
  - 
  - 
  3,417 
  - 
  3,417 
Option expense
  - 
  - 
  - 
  - 
  90,688 
  - 
  90,688 
Net loss
  - 
  - 
  - 
  - 
  - 
  (534,006)
  (534,006)
Balance at March 31, 2021
  - 
 $- 
  42,066,172 
 $420,662 
  5,055,420 
  (6,754,261)
  (1,278,179)
 
See accompanying notes to financial statements.
 
5
 
 
Ainos, Inc.
Condensed Statements of Cash Flows
(Unaudited)
 
 
 
Three months ended March 31,
 
 
 
2021
 
 
2020
 
 
 
 
 
 
 
 
Net cash used in operating activities
 $(115,712)
 $(119,482)
 
    
    
 
    
    
Cash flows from financing activities
    
    
     Proceeds from related party note
  102,844 
  - 
Net cash provided by financing activities
  102,844 
  - 
 
    
    
Net change in cash
  (12,868)
  (119,482)
Cash and cash equivalents at beginning of period
  22,245 
  409,039 
Cash and cash equivalents at end of period
  9,377 
 $289,557 
Supplemental Cash Flow Information
    
    
  Cash paid for interest
 $- 
 $- 
  Cash paid for income taxes
 $- 
 $- 
Non-Cash Transactions
    
    
Stock issued for accrued liabilities
 $- 
 $- 
Stock issued for advances from investors
 $- 
 $- 
Conversion of debt to common stock
 $- 
 $- 
 
See accompanying notes to financial statements.
 
6
 
Ainos, Inc.
Notes to Financial Statements
(Unaudited)
 
1.
Organization and Business. Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the "Company") is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. The Company is a Texas corporation which was formed in 1984.
 
2.
The Company primarily operates through three divisions:  Pharmaceutical, Medical and Consumer.  The Pharmaceutical division leverages our extensive library of clinical research by applying the Company's experience in the use of low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Company seeks to engage in patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing technology to treat metabolism related diseases such as type-1 and type-2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize a unique liposomal delivery system.  The Company currently has offices in the United States and Taiwan.  The Company operates in Taiwan under the name AMARILLO BIOSCIENCES, INC. TAIWAN BRANCH.
 
3.
Basis of presentation. The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021.
 
4.
Financial Condition. These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved sustained operating income, and its operations are funded primarily from related-party convertible debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.
 
The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.
 
 
7
 
 
There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.
 
5.
Common Stock. The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On March 31, 2021, a total of 51,383,130 shares of common stock were either issued (42,066,172), reserved for conversion of convertible debt to stock (4,032,919), issuance to two Company officers and consultants as compensation (174,422), and held for future exercise of nonqualified options and warrants (5,109,617).
 
We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future.
 
6.
Convertible Notes Payable and Other Related Party Notes Payable. As of December 31, 2020, the amount of convertible debt principal, on the Company’s balance sheet was $953,001. The total balance of the principal for convertible promissory notes as of March 31, 2021, is $915,016. This amount consisted of the following convertible promissory notes payable to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China, a consultant, as shown in the table below.
 
Note #.
 
Conversion Rate
 
 
Interest Rate
 
 
March 31, 2021
 
 
December 31, 2020
 
Note 1 - Chen
 $0.1680 
  0.75%
 $114,026 
 $114,026 
Note 2 - Chen
 $0.1875 
  0.65%
 $262,500 
 $262,500 
Note 3.19 - Chen
 $0.2500 
  1.85%
 $39,620 
 $39,620 
Note 4.19 - Chen
 $0.2500 
  1.61%
 $14,879 
 $14,879 
Note 5.19 – i2China
 $0.2500 
  1.85%
 $16,000 
 $16,000 
Note 6.20 - Chen
 $0.2500 
  1.85%
 $216,600 
 $216,600 
Note 7.20 - Chen
 $0.2500 
  1.60%
 $23,366 
 $23,366 
Note 8.20a – i2China
 $0.2500 
  1.85%
 $48,000 
 $48,000 
Note 8.20b – i2China
 $0.2500 
  1.85%
 $84,000 
 $84,000 
Note 9.21 - Chen
  N/A 
  0.13%
 $236,854 
 $134,010 
Note 10.21 – Chen
 $0.2500 
  1.85%
 $59,025 
  - 
Note 11 – i2China
 $0.2500 
  1.85%
 $37,000 
  - 
 
Total Convertible Notes (including accrued Interest) – Related Party
 
 $1,151,870 
 $953,001 
 
Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China Management Group, LLC, the Company’s management consultant, elected to defer cash compensation during a period of development and fundraising. The parties received convertible promissory notes in consideration of the deferrals.
 
 
8
 
 
On January 1, 2020, the Company issued Note #6.20 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $216,600, the maximum amount of cash compensation that could be deferred for 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $216,600 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity.
 
The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty.
 
On January 1, 2020, the Company issued Note #7.20 to Dr. Stephen T. Chen for deferred reimbursement of expenses advanced on behalf of the Company for $30,000, the maximum amount of reimbursable expense that could be deferred. Actual reimbursable expenses deferred is $23,366. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.60%. The note is an advancing note with a maximum limit of $30,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance against the Note, until Maturity, the amount submitted on a completed and approved reimbursement form along with documentation of the amount to be advanced. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Companuy’s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty.
 
On January 1, 2020, the Company issued Note #8.20 for deferred compensation to i2China Management Group, LLC in the amount of $48,000, the maximum amount of cash compensation that could be deferred in 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $48,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $4,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share.
 
On January 1, 2021, the Company issued Note #10.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $59,025. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR short-term rate of 1.85%. The note is an advancing note with a maximum limit of $59,025 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock.
__________
1 Applicable Federal Rate - the minimum interest rate that the Internal Revenue Service (IRS) allows for private loans. The IRS publishes a monthly set of interest rates that the agency considers the minimum market rate for loans, whereas, interest rates less than the AFR would have tax implications.
 
9
 
 
On January 1, 2021, the Company issued Note #11 for deferred compensation to i2China Management Group, LLC in the amount of $37,000. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $37,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $11,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share.
 
The notes are unsecured and are due on demand. All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen are related party notes.
 
7.
Other Related Party Transactions. Other than the aforementioned convertible notes activity, there were no related party transactions that occurred during the period from January 1, 2021 to March 31, 2021.
 
8.
Subsequent Events.
 
On April 1, 2021, the Company issued Note #11.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $18,050.  The Note is payable on May 1, 2021, or on demand and bears interest at the AFR[1] short-term rate of 1.85%.  The note is an advancing note with a maximum limit of $18,050 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures.  The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock.
 
On April 15, 2021, the Company consummated its Securities Purchase Agreement dated December 24, 2020 (“Ainos Agreement”) with a strategic investor, Ainos, Inc., a Cayman Islands corporation (“Investor”) focused on advanced technology diagnostic medical devices and artificial intelligence consumer healthcare solutions. Investor develops and manufactures point-of-care testing (“POCT”) rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection. Investor POCT delivers test results rapidly utilizing biosensors and artificial intelligence algorithms for volatile organic compound (VOC) analysis.  Pursuant to the Agreement, the Company issued 100,000,000 shares of common stock at $0.20 per share to Investor in exchange for certain patent assignments, increased its authorized common stock to 300,000,000 shares, and changed the Company’s name to “Ainos, Inc.” The Company’s prior Board of Directors resigned and seven (7) new board members were elected by our shareholders. In connection with the consummation of the transaction, Mr. Chun-Hsien Tsai was appointed to serve as the Company’s Chairman of Board, President, Chief Executive Officer and Chief Financial Officer. Mr. Chia-Hsi Chen was appointed to serve as the Company’s Chief Operating Officer effective as of April 15, 2021 but thereafter resigned effective as of April 28, 2021. Immediately after the consummation of the transaction and the issuance of the shares to the Investor, the Investor ownership in the Company is approximately 70.30% of the issued and outstanding shares of common stock of the Company. The foregoing description of the closing of the Ainos Agreement is not complete and is qualified in its entirety by the Form 8-K filed by the Company with the SEC on April 21, 2021, attached hereto as Exhibit 99.2 and which is incorporated herein by reference.
 
 
10
 
 
On April 27, 2021, the Company issued Note #12.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $15,000.  The Note is payable on October 27, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%.  The note has a maximum limit of $15,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity.  The Note may be convertible in whole or in part at a conversion price of $0.20 per share.
 
On April 28, 2021, Mr. Chia-Hsi Chen resigned as the Company’s Chief Operating Officer as of April 28, 2021 as reported by the Form 8-K filed by the Company with the SEC on May 3, 2021, attached hereto as Exhibit 99.3 and which is incorporated by reference.
 
On May 5, 2021, the Company issued Note #13.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $20,000.  The Note is payable on November 5, 2021, or on demand and bears interest at the Applicable Federal Rate (short-term rate) of 1.85%.  The note has a maximum limit of $20,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity.  The Note may be convertible in whole or in part at a conversion price of $0.20 per share.
 
Notes #11.21, #12.21, and #13.21 are un-secured and are due on demand.  All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933.  The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen and Ainos, Inc., a Cayman Islands Corporation are related party notes.
 
 
11
 
 
ITEM 2.    
Management's Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods.
 
Overview
 
Ainos, Inc. (the "Company”) is a Texas corporation formed in 1984 engaged in developing biologics for the treatment of human and animal diseases. Our current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using interferon (IFN) alpha that is administered in a proprietary low-dose non-injectable form. In addition to its core technology the Company is working to expand the Company’s current focus into a diversified healthcare business portfolio in order to generate new revenue streams.
 
The Company presently owns eight issued patents with two patents pending. This collection consists of patents with claims that encompass method of use or treatment, and/or composition of matter and manufacturing as well as design utility and/or invention. Of the eight issued patents, four patents are related to the low-dose oral delivery of interferon, one patent is for a product promoting oral health, and three patents are associated with treatment of metabolic disorders.
 
The Company primarily operates three business units: the Medical, Pharmaceutical, and Consumer Product Divisions. Historically, the Company has focused on R&D involving low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. The Company owns a proprietary library of over thirty years of scientific and clinical data on the human and animal applications of low-dose oral interferon. Through the Pharmaceutical Division, the Company seeks to out-license or leverage in other ways its core technology by forming partnerships to develop current and new discoveries and commercialize the resulting products.
 
An integral part of the company’s operating strategy is to create multiple revenue streams through the implementation of programs (including but not limited to in-licensing) of medical and healthcare products and therapeutics. The Medical Division and Consumer Products Division facilitate the enhancement of these revenue streams. These programs will be the catalysts that allow the Company to enter markets in Taiwan, Hong Kong, China, and other Asian countries for the distribution of new medical and healthcare products.
 
Over the past several years the Company has focused its research efforts towards the development of a novel pulsatile insulin pump infusion therapy in Taiwan that consists of delivering insulin intravenously in pulses, as opposed to the typical subcutaneous route of administration, in order to more closely imitate how the pancreas secretes insulin in healthy non-diabetics. The Company plans to offer an innovative and comprehensive diabetes treatment that provides solutions to all stages of diabetes from pre-diabetes through late-stage diabetes with advanced complications. The Company intends to target Taiwan first as an R&D base and demonstration platform in Greater China, and subsequently establish a licensing platform for clinics in Greater China. The Consumer Product Division is presently focused on sales of liposomal nutraceuticals and food supplements that include Vitamin C, Glutathione, CoQ10, Curcumin/Resveratrol, DHA, and a Multi-Vitamin.
 
 
12
 
 
The Company maintains a representative branch office in Taiwan – Amarillo Biosciences, Inc. (the “Taiwan Branch”) to increase the Company's presence in Taiwan and to serve as an operational hub to access growing Asian markets.
 
Injectable high-dose interferon is FDA-approved to treat some neoplastic, viral and autoimmune diseases.  Many patients experience moderate to severe side-effects causing them to discontinue injectable interferon therapy. Our core technology is primarily based on low-dose non-injectable interferon-alpha that is delivered into the oral cavity as a lozenge in low doses. The lozenge dissolves in the mouth where interferon binds to surface (mucosal) cells in the mouth and throat, resulting in activation of hundreds of genes in the peripheral blood that stimulate the immune system.  Human studies have shown that oral interferon is safe and effective against viral and neoplastic diseases. Oral interferon is given in concentrations 10,000 times less than that usually given by injection. The Company’s low-dose formulation results in almost no side effects, in contrast to high dose injectable interferon, which causes adverse effects in at least 50% of recipients.
 
Governmental or FDA approval is required for low-dose oral interferon. We believe that our technology is sound and can be commercialized for various indications. Due to lack of appropriate interferon supply in the market over the past several years, we have been unsuccessful at such commercialization to date. However, as a result of Covid-19, Chinese government health authorities have recommended use of anti-AIDS drugs and interferon. The Company believes this has brought renewed attention in the importance of incorporating low-dose interferon as a treatment to help stem the pandemic. In light of these circumstances, the Company is uniquely positioned to potentially develop safe, low-dose interferon.
 
While the pharmaceutical industry is creating and marketing new and effective anti-viral medications, there still exists opportunities to develop and commercialize low-dose interferon as a safer anti-viral treatment for influenza, hepatitis, and other conditions caused by viruses such as genital warts and canker sores. Interferon also has powerful cytotoxic effects which in combination with its immune stimulating activities could play a role in the rapidly expanding field of cancer immunotherapy. Other demonstrated effects of interferon offer opportunities to commercialize low-dose interferon for the treatment of Thrombocytopenia and chronic cough in lung diseases such as COPD and Idiopathic Pulmonary Fibrosis (IPF). The Company has the opportunity to capitalize on its relationship channels in the Asian markets to explore sources of raw materials, capital, production facilities, and to target a significant and growing sales market.
 
Ainos, Inc. Securities Purchase Agreement
 
On December 24, 2020, the Company entered into a Securities Purchase Agreement (“Ainos Agreement”) with Ainos, Inc., a Cayman Islands corporation (“Purchaser”) and certain principal shareholders of the Company including (i) Stephen T. Chen, individually and as Trustee of the Stephen T. Chen and Virginia M. Chen Living Trust, dated April 12, 2018, (ii) Virginia M. Chen, individually and as Trustee of the Stephen T. Chen and Virginia M. Chen Living Trust, dated April 12, 2018, and (iii) Hung Lan Lee (collectively, “Principal Shareholders”). 
 
 
13
 
 
Pursuant to the Ainos Agreement, upon the closing of the transactions contemplated thereby (the “Closing”), the Company will acquire certain patent assets (the “Patent Assets”) by issuing 100,000,000 shares of common stock (the “Shares”) valued at $0.20 to Purchaser.  The Patent Assets encompass technologies relating to development and manufacturing of point-of-care testing rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection.  The Company anticipates that the Shares issued to the Purchaser will represent approximately 70.30% of the issued and outstanding shares of common stock of the Company and effect a change of control in the Company at the Closing.  The Ainos Agreement provides for certain registration rights to the Purchaser regarding the Shares. 
 
The foregoing description of the Ainos Agreement is not complete and is qualified in its entirety by the text of the agreement, which is included as Exhibit 2.1 to the Form 8-K filed by the Company with the SEC on December 30, 2020, which is incorporated herein by reference.
 
On December 18, 2020, the Company Board, and on January 25, 2021, the holders owning a majority of the shares of common stock of the Company as of the record date of January 22, 2021 approved certain Company actions required under the Ainos Agreement. The Company filed a Form 14-C definitive information statement regarding the majority stockholder approval of the Company actions required for closing the Ainos transaction on March 19, 2021, which is incorporated herein by reference, and completed mailing of the information statements to its shareholders on March 26, 2021. The Company expects the Closing to occur on or after April 15, 2021, subject to the terms and conditions of the Ainos Agreement.
 
Patents and Proprietary Rights
 
Since inception, the Company has worked to build an extensive patent portfolio for low-dose orally administered interferon. This portfolio consists of patents with claims that encompass method of use or treatment, and/or composition of matter and manufacturing. As listed below, the Company presently owns eight issued patents with two patents pending.
 
ACTIVE PATENTS:
 
"TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON" as described and claimed in U.S. Patent No. 9,526,694 B2 issued December 27, 2016, Owned. Expiration: April 2033.
 
“TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON" as described and claimed in U.S. Patent No. 9,750,786 B2 issued September 5, 2017, Owned. Expiration: April 2033.
 
“TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON" as described and claimed in U.S. Patent No. 9,839,672 B2 issued December 12, 2017, Owned. Expiration: April 2033.
 
"TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON" as described and claimed in TAIWAN Patent No. I592165 issued July 21, 2017, Owned. Expiration: May 2033.
 
 
14
 
 
"COMPOSITION AND METHOD FOR PROMOTING ORAL HEALTH" as described and claimed in U.S. Patent No. 6,656,920 B2 issued December 2003, Owned. Expiration: April 2021.
 
“SMART DRUG INJECTION DEVICE” as described and claimed in TAIWAN invention patent application number 108137797, Owned, Issued: November 27, 2020, Expiration: October 18, 2039
 
“SMART DRUG INJECTION DEVICE” as described and claimed in TAIWAN design utility model patent application number 108213819, Owned, Issued: December 12, 2019, Expiration: November 11, 2038.
 
“SMART DRUG INJECTION DEVICE” as described and claimed in CHINA design utility model patent application number 201921808292.6, Owned, Issued: July 28, 2020, Expiration: June 27, 2039.
 
“SMART DRUG INJECTION DEVICE” as described and claimed in CHINA invention patent application number 201911024619.5, Pending.
 
“SMART DRUG INJECTION DEVICE” as described and claimed in US invention patent application number 17/069,418, Pending.
 
There are no current patent litigation proceedings involving the Company.
 
Cost of Compliance with Environmental Regulations
 
The Company incurred no costs to comply with environment regulations during the timeframe of this report.
 
United States Regulation
 
Before products with health claims can be marketed in the United States, they must receive approval from the U.S. Food and Drug Administration (“FDA”). To receive this approval, any drug must undergo rigorous preclinical testing and clinical trials that demonstrate the product candidate’s safety and effectiveness for each indicated use. This extensive regulatory process controls, among other things, the development, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale, and distribution of pharmaceutical products.
 
In general, before any ethical pharmaceutical product can be marketed in the United States, the FDA will require the following process:
 
Preclinical laboratory and animal tests;
Submission of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;
Adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use;
Pre-approval inspection of manufacturing facilities and selected clinical investigators;
Submission of a New Drug Application (NDA) to the FDA; and
FDA approval of an NDA, or of an NDA supplement (for subsequent indications or other modifications, including a change in location of the manufacturing facility).
 
 
15
 
 
Substantial financial resources are necessary to fund the research, clinical trials, and related activities necessary to satisfy FDA requirements or similar requirements of state, local, and foreign regulatory agencies. At such time as the Company undertakes to commercialize any of its products, all necessary preclinical testing, clinical trials, data review, and approval steps will be judiciously executed to insure that the product satisfies all regulatory requirements at all levels.
 
505(b)(2)
 
The Company has historically followed and will continue to follow the traditional approval process for New Drugs as set out in Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. If an alternative path to FDA approval for new or improved formulations of previously approved products is scientifically and economically feasible and beneficial to the Company and the public, the Company may choose to follow this alternative path as established by section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. This section of the Act permits the applicant to rely on certain preclinical or clinical studies conducted for an approved product as some of the information required for approval and for which the applicant has not obtained a right of reference. The process of approval under 505(b)(2) will be followed as judiciously as 505(b)(1) or any regulation.
 
Orphan Drug Designation
 
Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. The Company may choose to seek approval for a product satisfying the definition of an Orphan Drug if that product can be used to treat such an indication. Orphan drug designation does not convey any advantage in or shorten the duration or rigidity of the regulatory review and approval process.
 
Similarly, substantial financial resources are necessary to fund the research, design, testing, fabrication and related activities necessary to satisfy FDA requirements or similar requirements of state, local, and foreign regulatory agencies for medical devices. The Company may seek to obtain FDA clearance for the sales, marketing, and use of its novel pulsatile insulin pump for the U.S. market after obtaining FDA approvals under one of the following regulatory approvals:
 
Premarket Notification 510(k) 
 
Each person who intends to market in the U.S., a Class I, II, and III device intended for human use, for which a Premarket Approval application (“PMA”) is not required, must submit a 510(k) to FDA unless the device is exempt from 510(k) requirements of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”) and does not exceed the limitations of exemptions in .9 of the device classification regulation chapters (e.g., 21 CFR 862.9, 21 CFR 864.9).
 
If the Company’s novel pulsatile insulin pump is determined to be similar to one already cleared for the U.S. market, the Company will seek FDA clearance under 510(k) at least 90 days before the device is marketed. A 510(k) application requires demonstration of substantial equivalence to another legally U.S. marketed device. Substantial equivalence means that the new device is as safe and effective as the predicate. Documented laboratory testing among other submissions will be required and if the Company’s device features significant alterations from predecessor devices the Company may be required to present results from clinical trials.
 
 
16
 
 
Premarket Approval (PMA)
 
Alternatively, if the Company’s device is deemed to be completely new to the U.S. market or classified as a Class III device, the Company will be required to apply for PMA approval. The Medical Device Amendments of 1976 to the FD&C Act established three regulatory classes for medical devices. The three classes are based on the degree of control necessary to assure that the various types of devices are safe and effective. The most regulated devices are in Class III. The amendments define a Class III device as one that supports or sustains human life or is of substantial importance in preventing impairment of human health or presents a potential, unreasonable risk of illness or injury. 
 
Under Section 515 of the FD&C Act, all devices placed into Class III are subject to premarket approval requirements. Premarket approval by FDA is the required process of scientific review to ensure the safety and effectiveness of Class III devices.
 
Foreign Regulation
 
In addition to regulations in the United States, a variety of foreign regulations govern clinical trials and commercial sales and distribution of products in foreign countries. Whether or not the Company obtains FDA approval for a product, the Company must obtain approval of a product by the comparable regulatory authorities of foreign countries before the Company can commence clinical trials or market the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.
 
The policies of the FDA and foreign regulatory authorities may change and additional government regulations may be enacted which could prevent or delay regulatory approval of investigational drugs or approval of new diseases for existing products and could also increase the cost of regulatory compliance. It is not possible to predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.
 
Research and Development
 
During the quarter ended March 31, 2021 and the first quarter of 2020, the Company did not incur research and development expenses.
 
Employees
 
The Company currently has two full-time employees and two part-time employees. Of these four employees, two are executive officers and two work in administrative capacities.
 
Stephen T. Chen: Chairman, Chief Executive Officer (CEO), President and Chief Operating Officer (COO), and Chief Financial Officer (CFO). Dr. Chen was named Chairman of the Board in February 2012, and he has been a director of the Company since February 1996. He currently executes the management functions as not only Chairman, but as CEO, President, COO, and CFO.
 
 
17
 
 
Bernard Cohen: Vice President - Administration (VP-Admin). Mr. Cohen holds BBA and MPA degrees from West Texas A&M University. He is a long time Amarillo resident with over thirty years of management experience. Mr. Cohen has been with the Company since October 2009. Mr. Cohen works with Ms. Shelton, providing the reporting necessary for the Company’s various SEC filings, and ordinary-course internal bookkeeping and accounting services.
 
Chrystal Shelton: Office Manager & Administration. Ms. Shelton has been with the Company since 1987. In addition to handling routine office administration, Ms. Shelton is responsible for accounting, form, and formatting of SEC filings. She is an integral part of the reporting process and interacts with outside professionals who assist the Company in its various compliance measures.
 
Maggie Wang: Director of Business Development. Ms. Wang has an extensive background in business development and marketing of consumer products in Asian countries. Ms. Wang is also the branch manager for the Taiwan Branch.
 
Consultants
 
From time to time, the Company engages consultants as needed for specific areas of responsibility. Presently, the Company has engaged the following consultants: John Junyong Lee, Esq. - Chief Legal Counsel and Corporate Secretary, Dr. Yung-Hsiang Hung - Director-Medical Division; and i2China Management Group, LLC (Mr. Lawrence Lin)- Executive Advisor.
 
Results of Operations for Quarter Ended March 31, 2021 and 2020:
 
Revenues. The Company reported revenue for the quarter ended March 31, 2021, of $2,121 from sales of liposomal nutraceuticals. Revenue for the same period in 2020 was $15,200 also from sales of nutraceuticals. The cost of sales for the first quarter of 2021 was $1,249 as compared to $10,806 for cost of sales in 2020. Gross profit for the quarter in 2021 was $872 as compared to $4,394 in 2020, a decrease of $3,522.
 
Research and Development Expenses. There was no R&D activity in this quarter of 2021 or 2020.
 
Selling, General and Administrative Expenses. Selling, general and administrative expenses were $142,713 (38%) higher in 2021 than 2020 largely due to increased expenses associated with the Securities Purchase Agreement transaction with Ainos Inc.
 
Operating Loss. The Company's operating loss was $522,109 which was $146,235 (39%) higher for 2021 than 2020 mostly due to the expense of the Securities Purchase Agreement transaction with Ainos Inc.
 
Interest Expense. During the three months ended March 31, 2021, interest expense, net was $11,897, compared to $1,005 for the three months ended March 31, 2020. The interest expense recognized in the three months ended March 31, 2021 is mostly due to accrued interest for convertible debt notes.
 
Net Loss. Net loss attributable to common shareholders was $534,006 which was $157,127 (42%) higher during 2021 than 2020. This increase was mainly due to expenses related to processing of our Securities Purchase Agreement with Ainos Inc. in 2021.
 
 
18
 
 
Liquidity and Capital Resources
 
As of March 31, 2021, the Company had available cash of $9,377 whereas it had a cash position of $289,557 for the same period in 2020 and $22,245 as of December 31, 2020. The Company had a working capital deficit of $1,458,151 at the end of March 2021, and a working capital deficit of $580,993 for the same period in 2020, an increase of 151%. As of December 31, 2020, working capital was a deficit of $1,022,155. The average monthly burn rate in 2020 was $65,000. Going forward, we expect that the burn rate will continue to be in that same range.
 
The Company continues to develop and establish new revenue streams to become, and maintain, the position of a profitable going concern. Two major areas of focus are (1) to continue to leverage the Company’s core technology, the development and application of low-dose oral interferon, and (2) to commercialize its metabolic restoration therapy for the treatment of diabetes and other metabolic diseases. The Company aggressively seeks to monetize its existing intellectual property as well as potential new discoveries and estimates its short-term project development needs to be between $3,000,000 and $6,000,000 depending upon project negotiated terms and structuring yet to be determined.
 
There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, we will be forced to cease operations.
 
ITEM 3.   
Quantitative and Qualitative Disclosures About Market Risk.
 
As a “smaller reporting company,” we are not required to provide the information under this Item 3.
 
ITEM 4.    
Controls and Procedures
 
Disclosure Controls and Procedures
 
At the end of the period covered by this report, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2021. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
 
 
19
 
 
Management's Report on Internal Control Over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control - Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of March 31, 2021.
 
Changes in Internal Control Over Financial Reporting
 
We have not experienced any material impact to our internal controls over financial reporting even though our workforce continues to primarily work-from-home due to COVID-19. We are continually monitoring and assessing the COVID-19 situation and its impact on our internal controls.
 
This interim report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the SEC that permit the company to provide only management's report in this interim report.
 
 
PART II - OTHER INFORMATION
 
ITEM 1.         
Legal Proceedings.
 
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any such legal proceedings or claims against us.
 
ITEM 1A.
Risk Factors.
 
Please carefully consider the following discussion of significant factors, events, and uncertainties that make an investment in our securities risky. The events and consequences discussed in these risk factors could, in circumstances we may or may not be able to accurately predict, recognize, or control, have a material adverse effect on our business, growth, reputation, prospects, financial condition, operating results (including components of our financial results), cash flows, liquidity, and stock price. These risk factors do not identify all risks that we face; our operations could also be affected by factors, events, or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. In addition, the global economic climate amplifies many of these risks.
 
 
20
 
 
We Face Intense Competition
 
The pharmaceutical industry is an expanding and rapidly changing industry characterized by intense competition. The Company believes that our ability to compete will be dependent in large part upon our ability to successfully operate business lines, continue recapitalization, and steadily enhance and improve our core technology products. In order to do so, we must effectively utilize and expand our research and development capabilities and, once developed, quickly convert new technology into products and processes, which can then be commercialized. Competition is based primarily on scientific and technological superiority, technical support, availability of patent protection, access to adequate capital, the ability to develop, acquire and market products and processes successfully, the ability to obtain governmental approvals and the ability to serve the particular needs of commercial customers. Corporations and institutions with greater resources therefore, have a significant competitive advantage.
 
Our potential competitors include entities that develop and produce therapeutic agents and/or medical devices for treatment of human and animal disease. These include numerous public and private academic and research organizations and pharmaceutical and biotechnology companies pursuing production of, among other things, biologics from cell cultures, genetically engineered drugs and natural and chemically synthesized drugs. Many of these potential competitors have substantially greater capital resources, research and development capabilities, manufacturing and marketing resources. Competitors may succeed in developing products or processes that are more effective or less costly or that gain regulatory approval prior to our products. The Company expects that the number of competitors and potential competitors will increase as more anti-viral and cytotoxic products receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies. Any of these competitors may be more successful in manufacturing, marketing and distributing its products.
 
Our Expansion Places a Significant Strain on our Management, Operational, Financial, and Other Resources
 
Increasing our product and service offerings will require scaling our management, financial and research and development resources. The complexity of the current focus of our business on innovative biotechnologies and treatments can place significant strain on our management, personnel, operations, systems, technical performance, financial resources, and internal financial control and reporting functions, and our expansion increases these factors. Failure to manage growth effectively could damage our reputation, limit our growth, and negatively affect our operating results.
 
Our Expansion into New Products, Services, Technologies, and Geographic Regions Subjects Us to Additional Risks
 
We may have limited or no experience in our newer market segments, and our customers may not adopt our product or service offerings. These offerings, which can present new and difficult technology challenges, may subject us to claims if customers of these offerings experience service disruptions or failures or other quality issues. In addition, profitability, if any, in our newer activities may not meet our expectations, and we may not be successful enough in these newer activities to recoup our investments in them. Failure to realize the benefits of amounts we invest in new technologies, products, or services could result in the value of those investments being written down or written off.
 
 
21
 
 
Our International Operations Expose Us to a Number of Risks
 
We have relatively little operating experience and may not benefit from any first-to-market advantages or otherwise succeed. It is costly to establish, develop, and maintain international operations, sales and marketing channels, and research and development and licensing capacity. Our international operations may not become profitable on a sustained basis.
 
In addition to risks described elsewhere in this section, our international sales and operations are subject to a number of risks, including:
 
local economic and political conditions;
 
government regulation (such as regulation of our product and service offerings and of competition); restrictive governmental actions (such as trade protection measures, including export duties and quotas and custom duties and tariffs); nationalization; and restrictions on foreign ownership restrictions on sales or distribution of certain products or services and uncertainty regarding liability for products, services, and content, including uncertainty as a result of less Internet-friendly legal systems, local laws, lack of legal precedent, and varying rules, regulations, and practices regarding the physical and digital distribution of media products and enforcement of intellectual property rights;
 
business licensing or certification requirements, such as for imports, exports, medical devices and medical treatments;
 
limitations on the repatriation and investment of funds and foreign currency exchange restrictions;
 
difficulty in staffing, developing, and managing foreign operations as a result of distance, language, and cultural differences;
 
compliance with the U.S. Foreign Corrupt Practices Act and other applicable U.S. and foreign laws prohibiting corrupt payments to government officials and other third parties;
 
laws and policies of the U.S. and other jurisdictions affecting trade, foreign investment, loans, and taxes; and
 
geopolitical events, including war and terrorism.
 
Our Commercial Agreements, Strategic Alliances, and Other Business Relationships Expose Us to Risks
 
Our business growth depends on commercial agreements, strategic alliances, and business relationships. Under these agreements, we provide access to our research library and clinical data as part of licensing and sales and marketing agreements. These arrangements are complex and require substantial infrastructure capacity, personnel, and other resource commitments, which may limit the amount of business we can service. We may not be able to implement, maintain, and develop the components of these commercial relationships, which may include research and development, clinical trials, diagnostic software and hardware design, and engaging third parties to perform services.
 
 
22
 
 
Our licensing agreements partially dependent on the volume of the other company’s sales. Therefore, when the other company’s offerings are not successful, the compensation we receive may be lower than expected or the agreement may be terminated. Moreover, we may not be able to enter into additional or alternative commercial relationships and strategic alliances on favorable terms. We also may be subject to claims from businesses to which we provide these services if we are unsuccessful in implementing, maintaining, or developing these services.
 
We Face Significant Supply Risk
 
We are exposed to significant supply risks that may adversely affect our operating results. The Company’s long-time human interferon producer is no longer manufacturing interferon. Plans for further clinical trials and commercialization of a low-dose interferon product have been placed on hold until a new source of interferon is found. The Company is actively seeking a new manufacturing partner and exploring sourcing options with pharmaceutical companies that have a supply of either recombinant interferon or natural human interferon made in a similar manner, but from a different cell line as our previous product.
 
Procuring a new source of interferon may require additional studies to compare results to the Company’s research and further clinical trials will have to be performed. The Company’s inability to secure interferon supplies may adversely affect our operating results.
 
Government Regulation Is Evolving and Unfavorable Changes Could Harm Our Business
 
We are subject to general business regulations and laws, as well as regulations and laws specifically governing biologics, pharmaceuticals, and medical devices and treatments. A large number of jurisdictions regulate our operations, and the extent, nature, and scope of such regulations is evolving and expanding as the scope of our businesses expand. We are regularly subject to formal and informal reviews and investigations by governments and regulatory authorities under existing laws, regulations, or interpretations or pursuing new and novel approaches to regulate our operations. Unfavorable regulations, laws, decisions, or interpretations by government or regulatory authorities applying those laws and regulations, or inquiries, investigations, or enforcement actions threatened or initiated by them, could cause us to incur substantial costs, expose us to unanticipated civil and criminal liability or penalties (including substantial monetary fines), diminish the demand for, or availability of, our products and services, increase our cost of doing business, require us to change our business practices in a manner materially adverse to our business, damage our reputation, impede our growth, or otherwise have a material effect on our operations.
 
Claims, Litigation, Government Investigations, and Other Proceedings May Adversely Affect Our Business and Results of Operations
 
As a company focusing on diagnostics and treatments for a wide range of human health care needs, we may be subject to actual and threatened claims, litigation, reviews, investigations, and other proceedings, including proceedings by governments and regulatory authorities, involving a wide range of issues, including patent and other intellectual property matters, taxes, labor and employment, competition and antitrust, privacy and data protection, product liability, consumer protection, commercial disputes, goods and services offered by us and by third parties, and other matters. Any of these types of proceedings can have an adverse effect on us because of legal costs, disruption of our operations, diversion of management resources, negative publicity, and other factors. The outcomes of these matters are inherently unpredictable and subject to significant uncertainties. 
 
 
23
 
 
ITEM 2. 
Unregistered Sales of Equity Securities and Use of Proceeds.
 
The 2020-1 Private Placement Equity Security Offering was unanimously authorized and approved by Consent of the Company’s Board of Directors. The Company offered up to 5,208,334 shares of Common voting stock at a price of $0.192 per share for an aggregate amount of $1,000,000. That offering is currently open and still available for investment.
 
On July 28, 2020, Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, executed and submitted a Private Placement Memorandum for the purchase of 520,833 common voting shares at $0.192 per share through the Company’s 2020-1 Private Placement Stock Offering. The total amount of the investment subscription was $100,000 of which $85,000 was tendered to the Company by Dr. Chen subject to his payment of the balance of the subscription. Subsequently, the Company and Dr. Chen rescinded the subscription, the Company retained $85,000 previously tendered as an investment, and the Company included the foregoing amount in an open ended, non-convertible promissory note #9.21 as indicated item 6 (Convertible Notes Payable – Related Parties) in the Notes to Financial Statements.
 
ITEM 3. 
Defaults Upon Senior Securities.
 
None
 
ITEM 4. 
Mine Safety Disclosures.
 
Not applicable
 
ITEM 5. 
Other Information.
 
On March 31, 2021, the Company entered into Amendment No. 2 to an Employment Agreement dated December 30, 2020 and effective January 1, 2021 between the Company and Stephen T. Chen (“Chen Agreement”) that extended the agreement to the closing date of the Ainos Agreement and transaction, a copy of which is provided as Exhibit 10.1(l) in this report. The Chen Agreement was reported in the Company’s 10-K report filed with the SEC on March 30, 2021, and is incorporated by this reference.
 
On March 31, 2021, the Company entered into Amendment No. 1 to an Employment Agreement dated December 30, 2020 and effective January 1, 2021 between the Company and Bernard Cohen (“Cohen Agreement”) that extended the agreement to April 5, 2021, a copy of which is provided as Exhibit 10.1(m) in this report. The Cohen Agreement was reported in the Company’s 10-K report filed with the SEC on March 30, 2021, and is incorporated by this reference.
 
 
24
 
 
ITEM 6. 
Exhibits.
 
EXHIBIT INDEX
 
 
INCORPORATED BY REFERENCE
EXHIBIT NUMBER
DESCRIPTION
FILED WITH THIS FORM 10-K
FILING DATE WITH SEC
FORM
EXH #
HYPERLINK TO FILINGS
 
 
 
 
 
 
 
3.1(a)
Restated Certificate of Formation of the Company, dated and filed July 27, 2015
 
3/30/2016
10-K
3.i.
3.1(b)
Bylaws of the Company, as amended July 10, 2015
 
3/30/2016
10-K
3.ii.
4.1(a)
Specimen Common Stock Certificate
 
8/8/1996
SB-2
4.1
4.1(b)
Form of Underwriter’s Warrant
 
8/8/1996
SB-2
4.2
10.1(a)
2008 Stock Incentive Plan dated May 20, 2008
 
5/22/2008
S-8
10.1(11)
10.1(b)
2018 Employee Stock Option Plan
 
4/16/2019
10-K
10.72
10.1(c)
2018 Officer, Directors, Employees and Consultants Nonqualified Stock Option Plan
 
4/16/2019
10-K
10.73
10.1(c)
2018 Stock Option Agreement – Nonqualified Stock Option
 
4/16/2019
10-K
10.74
10.1(e)
2018 Stock Option Agreement – Employee Plan
 
4/16/2019
10-K
10.75
10.1(f)*
Employment Agreement between Company and Stephen T. Chen, Ph.D. dated 12/31/20 and effective 01/01/21
 
3/30/2021
10-K
10.1(f)
10.1(g)*
Amendment No. 1 to Employment Agreement between Company and Stephen T. Chen, Ph.D. effective 01/01/21
 
3/30/2021
10-K
10.1(g)
10.1(h)*
Employment Agreement between Company and Bernard Cohen dated 12/31/20 and effective 01/01/21
 
3/30/2021
10-K
10.1(h)
10.1(i)
Settlement Agreement and Mutual General Release, effective 12/24/20
 
3/30/2021
10-K
10.1(i)
10.1(j)*
Extension of the consulting agreement and pre-existing warrant certificate between the Company and i2China Management Group, LLC (originally dated April 15, 2018), dated November 30, 2020
 
3/30/2021
10-K
10.1(j)
 
 
25
 
 
10.1(k)
Securities Purchase Agreement between Company and Ainos, Inc., dated December 24, 2020
 
12/30/2020
8-K
2.1
Amendment No. 2 to Employment Agreement between Company and Stephen T. Chen, Ph.D. dated March 31, 2021
 X
 
 
 
 
Amendment No. 1 to Employment Agreement between Company and Bernard Cohen dated March 31, 2021
 X
 
 
 

13
Form 10-K for period ending December 31, 2020
 
3/30/2021
10-K
 
X
 
 
 
 
X
 
 
 
 
99.1
906 Certification
X
 
 
 
 
99.2
Form 8-K reporting on the closing of the Ainos Agreement and transaction
 
4/21/2021
8-K
 
99.3
Form 8-K reporting on the resignation of the Company’s Chief Operating Officer
 
5/3/21
8-K
 
101.INS
XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the XBRL document.
X
 
 
 
 
101.SCH
XBRL Taxonomy Extension Schema Document
X
 
 
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
X
 
 
 
 
101.DEF
XBRL Taxonomy Extension Definition Linkbase
X
 
 
 
 
101.LAB
XBRL Taxonomy Extension Label Linkbase
X
 
 
 
 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
X
 
 
 
 
104.1
Cover Page Interactive Data File
X
 
 
 
 
 
The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this filing.
 
+ Schedules (as similar attachments) have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K.
 
* Indicates a management contract or compensatory plan or arrangement.
 
 
26
 
 
SIGNATURES
 
Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
AINOS, INC.
 
 
 
 
 
Date: May 14, 2021
By:  
/s/ Chun-Hsien Tsai
 
 
 
Chun-Hsien Tsai, Chairman of the Board, 
 
 
 
Chief Executive Officer and Chief Financial Officer
 
 
 
 
 
 
 
 
 
 
 
 
27
EX-31.1 2 amar_ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 amar_ex311
 
EXHIBIT 31.1
FORM OF CERTIFICATION
PURSUANT TO RULE 13a-14 AND 15d-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
 
CERTIFICATION
 
I, Chun-Hsien Tsai, certify that:
 
1.           I have reviewed this report on Form 10-Q of Ainos, Inc.;
 
2.           Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;
 
3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.           The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
 
(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 14, 2021
 
/s/ Chun-Hsien Tsai
 
 
Chun-Hsien Tsai, Chairman of the Board,
Chief Executive Officer and Chief Financial Officer
 
 
EX-32.1 3 amar_ex321.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 amar_ex321
 
                  EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Ainos, Inc. on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
 
1.            
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2.            
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
 
 
   AINOS, INC.
 
Date: May 14, 2021
 
   By: /s/ Chun-Hsien Tsai                            
Chun-Hsien Tsai, Chairman of the Board,
and Chief Executive Officer
 
 
 
 
 
EX-10.1 4 amar_ex101l.htm AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT BETWEEN COMPANY AND STEPHEN T. CHEN, PH.D. DATED MARCH 31, 2021 amar_ex101l
  Exhibit 10.1 l
AMENDMENT NO. 2
TO
EMPLOYMENT AGREEMENT
 
THIS AMENDMENT NO. 2 is made by and between AMARILLO BIOSCIENCES, INC., a Texas corporation, inclusive of any Affiliates or subsidiaries (“ABI”) and STEPHEN T. CHEN, Ph.D. (“EMPLOYEE”) to that certain Employment Agreement between the parties made effective January 1, 2021 (“Agreement”).
 
1.
The term of the Agreement shall be extended to April 30, 2021.
 
2.
All other terms and conditions under the Agreement not expressly amended or modified by this amendment shall continue in full force and effect.
 
IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed:
 
 
Amarillo Biosciences, Inc.
EMPLOYEE:
 
 
By:     /s/ John Junyong Lee
By:  /s/ Stephen T. Chen
John Junyong Lee. Secretary
Stephen T. Chen, Ph.D.
 
 
Date: 3/31/2021
 Date: 3/31/2021  
 
 

EX-10.1 5 amar_ex101m.htm AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT BETWEEN COMPANY AND BERNARD COHEN DATED MARCH 31, 2021 amar_ex101m
  Exhibit 10.1m
AMENDMENT NO. 1
TO
EMPLOYMENT AGREEMENT
 
THIS AMENDMENT NO. 1 is made by and between AMARILLO BIOSCIENCES, INC., a Texas corporation, inclusive of any Affiliates or subsidiaries (“ABI”) and BERNARD COHEN (“EMPLOYEE”) to that certain Employment Agreement between the parties made effective January 1, 2021 (“Agreement”).
 
1.
The term of the Agreement shall be extended to April 5, 2021.
 
2.
Employee may serve in any capacity as an officer of ABI as determined by ABI’s Board of Directors and Article III of ABI’s Bylaws.
 
3.
All other terms and conditions under the Agreement not expressly amended or modified by this amendment shall continue in full force and effect.
 
IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of March 31 2021:
 
Amarillo Biosciences, Inc.
EMPLOYEE:
 
 
By:     /s/ John Junyong Lee
By:    /s/ Bernard Cohen
John Junyong Lee. Secretary
Bernard Cohen
 

EX-101.INS 6 amar-20210331.xml XBRL INSTANCE DOCUMENT 0001014763 2021-03-31 0001014763 2021-01-01 2021-03-31 0001014763 2020-12-31 0001014763 2020-01-01 2020-03-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001014763 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001014763 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001014763 us-gaap:PreferredStockMember 2020-12-31 0001014763 us-gaap:CommonStockMember 2020-12-31 0001014763 us-gaap:PreferredStockMember 2021-03-31 0001014763 us-gaap:CommonStockMember 2021-03-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001014763 us-gaap:RetainedEarningsMember 2020-12-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001014763 us-gaap:RetainedEarningsMember 2021-03-31 0001014763 amar:ConvertibleNotePayableOneMember 2021-03-31 0001014763 amar:ConvertibleNotePayableTwoMember 2021-03-31 0001014763 amar:ConvertibleNotePayableThreeMember 2021-03-31 0001014763 amar:ConvertibleNotePayableFourMember 2021-03-31 0001014763 amar:ConvertibleNotePayableFiveMember 2021-03-31 0001014763 amar:ConvertibleNotePayableSixMember 2021-03-31 0001014763 amar:ConvertibleNotePayableSevenMember 2021-03-31 0001014763 amar:ConvertibleNotePayableEightAMember 2021-03-31 0001014763 amar:ConvertibleNotePayableEightBMember 2021-03-31 0001014763 amar:ConvertibleNotePayableNineMember 2021-03-31 0001014763 amar:ConvertibleNotePayableTenMember 2021-03-31 0001014763 amar:ConvertibleNotePayableElevenMember 2021-03-31 0001014763 amar:ConvertibleNotePayableOneMember 2020-12-31 0001014763 amar:ConvertibleNotePayableTwoMember 2020-12-31 0001014763 amar:ConvertibleNotePayableThreeMember 2020-12-31 0001014763 amar:ConvertibleNotePayableFourMember 2020-12-31 0001014763 amar:ConvertibleNotePayableFiveMember 2020-12-31 0001014763 amar:ConvertibleNotePayableSixMember 2020-12-31 0001014763 amar:ConvertibleNotePayableSevenMember 2020-12-31 0001014763 amar:ConvertibleNotePayableEightAMember 2020-12-31 0001014763 amar:ConvertibleNotePayableEightBMember 2020-12-31 0001014763 amar:ConvertibleNotePayableNineMember 2020-12-31 0001014763 amar:ConvertibleNotePayableTenMember 2020-12-31 0001014763 amar:ConvertibleNotePayableElevenMember 2020-12-31 0001014763 us-gaap:PreferredStockMember 2019-12-31 0001014763 us-gaap:PreferredStockMember 2020-03-31 0001014763 us-gaap:CommonStockMember 2019-12-31 0001014763 us-gaap:CommonStockMember 2020-03-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001014763 us-gaap:RetainedEarningsMember 2019-12-31 0001014763 us-gaap:RetainedEarningsMember 2020-03-31 0001014763 2019-12-31 0001014763 2020-03-31 0001014763 2021-05-14 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the &#34;Company&#34;) is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. The Company is a Texas corporation which was formed in 1984.</p> <p style="margin: 0; font-size: 8pt"><font style="font-family: Times New Roman, Times, Serif">The Company primarily operates through three divisions:&#160; Pharmaceutical, Medical and Consumer.&#160; The Pharmaceutical division leverages our extensive library of clinical research by applying the Company's experience in the use of low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Company seeks to engage in patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing technology to treat metabolism related diseases such as type-1 and type-2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize a unique liposomal delivery system.&#160; The Company currently has offices in the United States and Taiwan.&#160; The Company operates in Taiwan under the name AMARILLO BIOSCIENCES, INC. TAIWAN BRANCH (</font><font style="font-family: MS Mincho">&#32654;&#21830;&#24247;&#33775;&#20840;&#29699;&#29983;&#25216;&#32929;</font><font style="font-family: MS Gothic, Helvetica, Sans-Serif">&#20221;&#26377;&#38480;&#20844;&#21496;</font><font style="font-family: Times New Roman, Times, Serif">&#160;</font><font style="font-family: MS Mincho">&#21488;&#28771;&#20998;&#20844;&#21496;</font><font style="font-family: Times New Roman, Times, Serif">).</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved sustained operating income, and its operations are funded primarily from related-party convertible debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 1.5pt 0 27pt; text-align: justify">The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On March 31, 2021, a total of 51,383,130 shares of common stock were either issued (42,066,172), reserved for conversion of convertible debt to stock (4,032,919), issuance to two Company officers and consultants as compensation (174,422), and held for future exercise of nonqualified options and warrants (5,109,617).</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 1.5pt 0 27pt; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 1.5pt 0 27pt; text-align: justify">We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future.</p> <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 36px"><font style="font-size: 8pt"></font></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt"><b>Convertible Notes Payable and Other Related Party Notes Payable.</b> As of December 31, 2020, the amount of convertible debt principal, on the Company&#8217;s balance sheet was $953,001. The total balance of the principal for convertible promissory notes as of March 31, 2021, is $915,016. This amount consisted of the following convertible promissory notes payable to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China, a consultant, as shown in the table below.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt; text-align: center"><font style="font-size: 8pt"><b>Note #.</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Conversion Rate</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Interest Rate</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2021</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2020</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%; padding-right: 1.5pt"><font style="font-size: 8pt">Note 1 - Chen</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">0.1680</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">0.75</font></td> <td style="width: 1%"><font style="font-size: 8pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">114,026</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">114,026</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 2 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.1875</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0.65</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">262,500</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">262,500</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 3.19 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">39,620</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">39,620</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 4.19 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.61</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">14,879</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">14,879</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 5.19 &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 6.20 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">216,600</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">216,600</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 7.20 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.60</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">23,366</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">23,366</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 8.20a &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">48,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">48,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 8.20b &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">84,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">84,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 9.21 - Chen</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0.13</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">236,854</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">134,010</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 10.21 &#8211; Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">59,025</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 11 &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">37,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td>&#160;</td></tr> <tr> <td colspan="3" style="vertical-align: bottom"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 1.5pt 0 0">Total Convertible Notes (including accrued Interest) &#8211; Related Party</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1,151,870</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">953,001</font></td> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China Management Group, LLC, the Company&#8217;s management consultant, elected to defer cash compensation during a period of development and fundraising. The parties received convertible promissory notes in consideration of the deferrals.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">On January 1, 2020, the Company issued Note #6.20 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $216,600, the maximum amount of cash compensation that could be deferred for 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $216,600 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company&#8217;s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">On January 1, 2020, the Company issued Note #7.20 to Dr. Stephen T. Chen for deferred reimbursement of expenses advanced on behalf of the Company for $30,000, the maximum amount of reimbursable expense that could be deferred. Actual reimbursable expenses deferred is $23,366. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.60%. The note is an advancing note with a maximum limit of $30,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance against the Note, until Maturity, the amount submitted on a completed and approved reimbursement form along with documentation of the amount to be advanced. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Companuy&#8217;s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">On January 1, 2020, the Company issued Note #8.20 for deferred compensation to i2China Management Group, LLC in the amount of $48,000, the maximum amount of cash compensation that could be deferred in 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $48,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $4,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">On January 1, 2021, the Company issued Note #10.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $59,025. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR short-term rate of 1.85%. The note is an advancing note with a maximum limit of $59,025 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company&#8217;s common voting stock.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">__________</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">1 Applicable Federal Rate -<font style="color: #222222; background-color: white">&#160;</font>the<font style="color: #222222; background-color: white">&#160;</font>minimum interest rate that the Internal Revenue Service (IRS) allows for private loans. The IRS publishes a monthly set of interest&#160;rates&#160;that the agency considers the minimum market rate for loans, whereas, interest rates less than the&#160;AFR&#160;would have tax implications.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">On January 1, 2021, the Company issued Note #11 for deferred compensation to i2China Management Group, LLC in the amount of $37,000. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $37,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $11,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">The notes are unsecured and are due on demand. All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen are related party notes.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Other than the aforementioned convertible notes activity, there were no related party transactions that occurred during the period from January 1, 2021 to March 31, 2021.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="color: #222222">On April 1, 2021, the Company issued Note #11.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $18,050.&#160;&#160;The Note is payable on May 1, 2021, or on demand and bears interest at the AFR</font><font style="color: #1155CC"><u>[1]</u></font><font style="color: #222222">&#160;short-term rate of 1.85%.&#160;&#160;The note is an advancing note with a maximum limit of $18,050 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures.&#160;&#160;The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company&#8217;s common voting stock.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><font style="color: #222222">On April 15, 2021, the Company</font> consummated its Securities Purchase Agreement dated December 24, 2020 (&#8220;Ainos Agreement&#8221;) with a strategic investor, Ainos, Inc., a Cayman Islands corporation (&#8220;Investor&#8221;) focused on advanced technology diagnostic medical devices and artificial intelligence consumer healthcare solutions. Investor develops and manufactures point-of-care testing (&#8220;POCT&#8221;) rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection. Investor POCT delivers test results rapidly utilizing biosensors and artificial intelligence algorithms for volatile organic compound (VOC) analysis.<font style="color: #1F497D">&#160;</font> Pursuant to the Agreement, the Company issued 100,000,000 shares of common stock at $0.20 per share to Investor in exchange for certain patent assignments, increased its authorized common stock to 300,000,000 shares, and changed the Company&#8217;s name to &#8220;Ainos, Inc.&#8221; The Company&#8217;s prior Board of Directors resigned and seven (7) new board members were elected by our shareholders. In connection with the consummation of the transaction, Mr. Chun-Hsien Tsai was appointed to serve as the Company&#8217;s Chairman of Board, President, Chief Executive Officer and Chief Financial Officer. Mr. Chia-Hsi Chen was appointed to serve as the Company&#8217;s Chief Operating Officer effective as of April 15, 2021 but thereafter resigned effective as of April 28, 2021. Immediately after the consummation of the transaction and the issuance of the shares to the Investor, the Investor ownership in the Company is approximately 70.30% of the issued and outstanding shares of common stock of the Company. The foregoing description of the closing of the Ainos Agreement is not complete and is qualified in its entirety by the Form 8-K filed by the Company with the SEC on April 21, 2021, attached hereto as Exhibit 99.2 and which is incorporated herein by reference.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; color: #222222">On April 27, 2021, the Company issued Note #12.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $15,000.&#160;&#160;The Note is payable on October 27, 2021, or on demand and bears interest at the AFR1&#160;short-term rate of 1.85%.&#160;&#160;The note has a maximum limit of $15,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity.&#160;&#160;The Note may be convertible in whole or in part at a conversion price of $0.20 per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; color: #222222">On April 28, 2021, Mr. Chia-Hsi Chen resigned as the Company&#8217;s Chief Operating Officer as of April 28, 2021 as reported by the Form 8-K filed by the Company with the SEC on May 3, 2021, attached hereto as Exhibit 99.3 and which is incorporated by reference.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; color: #222222">On May 5, 2021, the Company issued Note #13.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $20,000.&#160;&#160;The Note is payable on November 5, 2021, or on demand and bears interest at the Applicable Federal Rate&#160;(short-term rate) of 1.85%.&#160;&#160;The note has a maximum limit of $20,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity.&#160;&#160;The Note may be convertible in whole or in part at a conversion price of $0.20 per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">Notes <font style="color: #222222">#11.21, #12.21, and #13.21</font> are un-secured and are due on demand.&#160;&#160;<font style="color: #222222">All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933.&#160;&#160;The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen and Ainos, Inc., a Cayman Islands Corporation are related party notes.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt; text-align: center"><font style="font-size: 8pt"><b>Note #.</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Conversion Rate</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Interest Rate</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2021</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2020</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%; padding-right: 1.5pt"><font style="font-size: 8pt">Note 1 - Chen</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">0.1680</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">0.75</font></td> <td style="width: 1%"><font style="font-size: 8pt">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">114,026</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">114,026</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 2 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.1875</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0.65</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">262,500</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">262,500</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 3.19 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">39,620</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">39,620</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 4.19 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.61</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">14,879</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">14,879</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 5.19 &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 6.20 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">216,600</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">216,600</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 7.20 - Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.60</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">23,366</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">23,366</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 8.20a &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">48,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">48,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 8.20b &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">84,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">84,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 9.21 - Chen</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">0.13</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">236,854</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">134,010</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 10.21 &#8211; Chen</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">59,025</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 1.5pt"><font style="font-size: 8pt">Note 11 &#8211; i2China</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.2500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.85</font></td> <td><font style="font-size: 8pt">%</font></td> <td>&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">37,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">-</font></td> <td>&#160;</td></tr> <tr> <td colspan="3" style="vertical-align: bottom"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0 1.5pt 0 0">Total Convertible Notes (including accrued Interest) &#8211; Related Party</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1,151,870</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom"><font style="font-size: 8pt">$</font></td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">953,001</font></td> <td style="vertical-align: bottom">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> 915016 953001 114026 262500 39620 14879 16000 216600 23366 48000 84000 236854 59025 37000 114026 262500 39620 14879 16000 216600 23366 48000 84000 134010 0 0 1151870 953001 0.0075 0.0065 0.0185 0.0161 0.0185 0.0185 0.016 0.0185 0.0185 0.0013 0.0185 0.0185 0.168 0.1875 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0 0.25 0.25 42267 76413 32890 51144 0 3024 9377 22245 222239 260290 2921 3249 177051 180628 1500418 1098568 236854 0 348548 145567 1500418 1098568 0 0 -1278179 -838278 -6754261 -6220255 5055420 4961315 420662 420662 222239 260290 0.01 0.01 10000000 10000000 0 0 0 0 0.01 0.01 100000000 100000000 42066172 42066172 42066172 42066172 872 4394 1249 10806 2121 15200 -522981 -380268 -522981 -380268 -522109 -375874 -534006 -376879 -534006 -376879 -11897 -1005 -534006 -376879 0 0 -0.01 -0.01 42066172 40516351 0 42066172 0 42066172 0 0 40516351 40516351 -1278179 -838278 0 420662 0 420662 4961315 -6220255 5055420 -6754261 0 0 405164 405164 4207786 4307970 -4769632 -5146511 -156682 -433377 3417 9496 3417 9496 90688 90688 90688 90688 -119482 -115712 0 102844 0 102844 289557 409039 22245 9377 -119482 -12868 0 0 0 0 0 0 0 0 0 0 42066172 4032919 174422 5109617 Ainos, Inc. 0001014763 --12-31 Non-accelerated Filer No false true Yes 142240594 false 10-Q 2021-03-31 Q1 2021 false TX 0-20791 EX-101.SCH 7 amar-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 1 - Organization and Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 2 - General link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 3 - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 - Financial Condition link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 5 - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 6 - Convertible Notes Payable and Other Related Party Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 7 - Other Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 8 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 6 - Convertible Notes Payable and Other Related Party Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 5 - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 6 - Convertible Notes Payable - Related Party (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 6 - Convertible Notes Payable - Related Party - Convertible Notes Payable, Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 amar-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 amar-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 amar-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Equity Components [Axis] Additional Paid-in Capital Accumulated Deficit Preferred Stock Common Stock Debt Instrument [Axis] Note 1 Note 2 Note 3 Note 4 Note 5 Note 6 Note 7 Note 8a Note 8b Note 9 Note 10 Note 11 Cover [Abstract] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Current Reporting Status Entity Emerging Growth Company Entity Small Business Entity Interactive Data Current Entity Common Stock, Shares Outstanding (in shares) Entity Shell Company Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Entity Incorporation, State or Country Code Entity File Number Statement of Financial Position [Abstract] Assets Cash and cash equivalents Inventory Prepaid expense and other current assets Total current assets Patents, net Property and equipment, net Total assets Liabilities and Stockholders' Equity (Deficit) Accounts payable and accrued expenses Notes payable - related party Convertible notes payable – related party Total current liabilities Total liabilities Stockholders' equity (deficit) Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at March 31, 2021 and December 31, 2020 Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 42,066,172 and 42,066,172 at March 31, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Preferred stock, par value (in dollars per share) Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Income Statement [Abstract] Revenues Cost of revenues Gross margin Operating expenses: Selling, general and administrative expenses Total operating expenses Operating loss Other income (expense) Interest income (expense), net Net income (loss) Less: Net Income attributable to non-controlling interests Net loss attributable to common shareholders Basic and diluted net loss per average share available to common shareholders (in dollars per share) Weighted average common shares outstanding – basic and diluted (in shares) Statement [Table] Statement [Line Items] Balance (in shares) Balance Warrant expense Option expense Net loss Balance (in shares) Balance Statement of Cash Flows [Abstract] Net cash used in operating activities Cash flows from financing activities Proceeds from related party note Net cash used in financing activities Net change in cash Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental Cash Flow Information Cash paid for interest Cash paid for income taxes Non-Cash Transactions Stock issued for accrued liabilities Stock issued for advances from investors Conversion of debt to common stock Notes To Financial Statements [Abstract] Notes to Financial Statements Organization and Business General Basis of Presentation Financial Condition Stockholders' Equity Attributable to Parent [Abstract] Common Stock Convertible Notes Payable [Abstract] Convertible Notes Payable and Other Related Party Notes Payable Related Party Transactions [Abstract] Other Related Party Transactions Subsequent Events [Abstract] Subsequent Events Notes Tables Convertible Debt Stock issued during period Shares reserved for conversion of convertible debt to stock Stock issued as compensation Shares held for furutre exercise of noqualified options and warrants Notes Payable, Convertible, Related Parties, Classified Current Convertible Notes Payable, Total Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Convertible, Conversion Price (in dollars per share) Convertible note payable Represents Assyrea Ltd. Disclosure on the Financial Condition of the company. Represents Hen Vai Wu. The amount for convertible notes payable (written promise to pay and including a conversion feature), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). The fair value of stock issued for accrued liabilities in noncash financing activities. The fair value of stock issued for advances from investors in noncash financing activities. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Cost of Revenue Gross Profit Selling, General and Administrative Expense Operating Expenses Operating Income (Loss) Shares, Outstanding Stockholders' Equity Attributable to Parent Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Stockholders' Equity Note Disclosure [Text Block] EX-101.PRE 11 amar-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2021
May 14, 2021
Cover [Abstract]    
Entity Registrant Name Ainos, Inc.  
Entity Central Index Key 0001014763  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Current Reporting Status No  
Entity Emerging Growth Company false  
Entity Small Business true  
Entity Interactive Data Current Yes  
Entity Common Stock, Shares Outstanding (in shares)   142,240,594
Entity Shell Company false  
Document Type 10-Q  
Document Period End Date Mar. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Incorporation, State or Country Code TX  
Entity File Number 0-20791  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheets - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Assets    
Cash and cash equivalents $ 9,377 $ 22,245
Inventory 0 3,024
Prepaid expense and other current assets 32,890 51,144
Total current assets 42,267 76,413
Patents, net 177,051 180,628
Property and equipment, net 2,921 3,249
Total assets 222,239 260,290
Liabilities and Stockholders' Equity (Deficit)    
Accounts payable and accrued expenses 348,548 145,567
Notes payable - related party 236,854 0
Convertible notes payable – related party 915,016 953,001
Total current liabilities 1,500,418 1,098,568
Total liabilities 1,500,418 1,098,568
Stockholders' equity (deficit)    
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at March 31, 2021 and December 31, 2020 0 0
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 42,066,172 and 42,066,172 at March 31, 2021 and December 31, 2020, respectively 420,662 420,662
Additional paid-in capital 5,055,420 4,961,315
Accumulated deficit (6,754,261) (6,220,255)
Total stockholders’ equity (deficit) (1,278,179) (838,278)
Total liabilities and stockholders’ equity (deficit) $ 222,239 $ 260,290
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 42,066,172 42,066,172
Common stock, shares outstanding (in shares) 42,066,172 42,066,172
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Revenues $ 2,121 $ 15,200
Cost of revenues (1,249) (10,806)
Gross margin 872 4,394
Operating expenses:    
Selling, general and administrative expenses 522,981 380,268
Total operating expenses 522,981 380,268
Operating loss (522,109) (375,874)
Other income (expense)    
Interest income (expense), net (11,897) (1,005)
Net income (loss) (534,006) (376,879)
Less: Net Income attributable to non-controlling interests 0 0
Net loss attributable to common shareholders $ (534,006) $ (376,879)
Basic and diluted net loss per average share available to common shareholders (in dollars per share) $ (0.01) $ (0.01)
Weighted average common shares outstanding – basic and diluted (in shares) 42,066,172 40,516,351
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance (in shares) at Dec. 31, 2019 0 40,516,351      
Balance at Dec. 31, 2019 $ 0 $ 405,164 $ 4,207,786 $ (4,769,632) $ (156,682)
Warrant expense     9,496   9,496
Option expense     90,688   90,688
Net loss       (376,879) (376,879)
Balance (in shares) at Mar. 31, 2020 0 40,516,351      
Balance at Mar. 31, 2020 $ 0 $ 405,164 4,307,970 (5,146,511) (433,377)
Balance (in shares) at Dec. 31, 2020 0 42,066,172      
Balance at Dec. 31, 2020 $ 0 $ 420,662 4,961,315 (6,220,255) (838,278)
Warrant expense     3,417   3,417
Option expense     90,688   90,688
Net loss       (534,006) (534,006)
Balance (in shares) at Mar. 31, 2021 0 42,066,172      
Balance at Mar. 31, 2021 $ 0 $ 420,662 $ 5,055,420 $ (6,754,261) $ (1,278,179)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement of Cash Flows [Abstract]    
Net cash used in operating activities $ (119,482) $ (115,712)
Cash flows from financing activities    
Proceeds from related party note 0 102,844
Net cash used in financing activities 0 102,844
Net change in cash (119,482) (12,868)
Cash and cash equivalents at beginning of period 409,039 22,245
Cash and cash equivalents at end of period 289,557 9,377
Supplemental Cash Flow Information    
Cash paid for interest 0 0
Cash paid for income taxes 0 0
Non-Cash Transactions    
Stock issued for accrued liabilities 0 0
Stock issued for advances from investors 0 0
Conversion of debt to common stock $ 0 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Business
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Organization and Business

Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the "Company") is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. The Company is a Texas corporation which was formed in 1984.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - General
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
General

The Company primarily operates through three divisions:  Pharmaceutical, Medical and Consumer.  The Pharmaceutical division leverages our extensive library of clinical research by applying the Company's experience in the use of low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Company seeks to engage in patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing technology to treat metabolism related diseases such as type-1 and type-2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize a unique liposomal delivery system.  The Company currently has offices in the United States and Taiwan.  The Company operates in Taiwan under the name AMARILLO BIOSCIENCES, INC. TAIWAN BRANCH (美商康華全球生技股份有限公司 台灣分公司).

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Basis of Presentation
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Basis of Presentation

The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Financial Condition
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Financial Condition

 

These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved sustained operating income, and its operations are funded primarily from related-party convertible debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.

 

The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

 

There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Common Stock
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Common Stock

 

The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On March 31, 2021, a total of 51,383,130 shares of common stock were either issued (42,066,172), reserved for conversion of convertible debt to stock (4,032,919), issuance to two Company officers and consultants as compensation (174,422), and held for future exercise of nonqualified options and warrants (5,109,617).

 

We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Convertible Notes Payable and Other Related Party Notes Payable
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Convertible Notes Payable and Other Related Party Notes Payable
Convertible Notes Payable and Other Related Party Notes Payable. As of December 31, 2020, the amount of convertible debt principal, on the Company’s balance sheet was $953,001. The total balance of the principal for convertible promissory notes as of March 31, 2021, is $915,016. This amount consisted of the following convertible promissory notes payable to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China, a consultant, as shown in the table below.

 

Note #.   Conversion Rate     Interest Rate     March 31, 2021     December 31, 2020  
Note 1 - Chen   $ 0.1680       0.75 %   $ 114,026     $ 114,026  
Note 2 - Chen   $ 0.1875       0.65 %   $ 262,500     $ 262,500  
Note 3.19 - Chen   $ 0.2500       1.85 %   $ 39,620     $ 39,620  
Note 4.19 - Chen   $ 0.2500       1.61 %   $ 14,879     $ 14,879  
Note 5.19 – i2China   $ 0.2500       1.85 %   $ 16,000     $ 16,000  
Note 6.20 - Chen   $ 0.2500       1.85 %   $ 216,600     $ 216,600  
Note 7.20 - Chen   $ 0.2500       1.60 %   $ 23,366     $ 23,366  
Note 8.20a – i2China   $ 0.2500       1.85 %   $ 48,000     $ 48,000  
Note 8.20b – i2China   $ 0.2500       1.85 %   $ 84,000     $ 84,000  
Note 9.21 - Chen     N/A       0.13 %   $ 236,854     $ 134,010  
Note 10.21 – Chen   $ 0.2500       1.85 %   $ 59,025       -  
Note 11 – i2China   $ 0.2500       1.85 %   $ 37,000       -  

 

Total Convertible Notes (including accrued Interest) – Related Party

 

  $ 1,151,870     $ 953,001              

 

Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China Management Group, LLC, the Company’s management consultant, elected to defer cash compensation during a period of development and fundraising. The parties received convertible promissory notes in consideration of the deferrals.

 

On January 1, 2020, the Company issued Note #6.20 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $216,600, the maximum amount of cash compensation that could be deferred for 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $216,600 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity.

 

The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty.

 

On January 1, 2020, the Company issued Note #7.20 to Dr. Stephen T. Chen for deferred reimbursement of expenses advanced on behalf of the Company for $30,000, the maximum amount of reimbursable expense that could be deferred. Actual reimbursable expenses deferred is $23,366. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.60%. The note is an advancing note with a maximum limit of $30,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance against the Note, until Maturity, the amount submitted on a completed and approved reimbursement form along with documentation of the amount to be advanced. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Companuy’s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty.

 

On January 1, 2020, the Company issued Note #8.20 for deferred compensation to i2China Management Group, LLC in the amount of $48,000, the maximum amount of cash compensation that could be deferred in 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $48,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $4,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share.

 

On January 1, 2021, the Company issued Note #10.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $59,025. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR short-term rate of 1.85%. The note is an advancing note with a maximum limit of $59,025 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock.

__________

1 Applicable Federal Rate - the minimum interest rate that the Internal Revenue Service (IRS) allows for private loans. The IRS publishes a monthly set of interest rates that the agency considers the minimum market rate for loans, whereas, interest rates less than the AFR would have tax implications.

 

On January 1, 2021, the Company issued Note #11 for deferred compensation to i2China Management Group, LLC in the amount of $37,000. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $37,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $11,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share.

 

The notes are unsecured and are due on demand. All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen are related party notes.

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Other Related Party Transactions
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Other Related Party Transactions

Other than the aforementioned convertible notes activity, there were no related party transactions that occurred during the period from January 1, 2021 to March 31, 2021.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Subsequent Events
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Subsequent Events

On April 1, 2021, the Company issued Note #11.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $18,050.  The Note is payable on May 1, 2021, or on demand and bears interest at the AFR[1] short-term rate of 1.85%.  The note is an advancing note with a maximum limit of $18,050 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures.  The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock.

 

On April 15, 2021, the Company consummated its Securities Purchase Agreement dated December 24, 2020 (“Ainos Agreement”) with a strategic investor, Ainos, Inc., a Cayman Islands corporation (“Investor”) focused on advanced technology diagnostic medical devices and artificial intelligence consumer healthcare solutions. Investor develops and manufactures point-of-care testing (“POCT”) rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection. Investor POCT delivers test results rapidly utilizing biosensors and artificial intelligence algorithms for volatile organic compound (VOC) analysis.  Pursuant to the Agreement, the Company issued 100,000,000 shares of common stock at $0.20 per share to Investor in exchange for certain patent assignments, increased its authorized common stock to 300,000,000 shares, and changed the Company’s name to “Ainos, Inc.” The Company’s prior Board of Directors resigned and seven (7) new board members were elected by our shareholders. In connection with the consummation of the transaction, Mr. Chun-Hsien Tsai was appointed to serve as the Company’s Chairman of Board, President, Chief Executive Officer and Chief Financial Officer. Mr. Chia-Hsi Chen was appointed to serve as the Company’s Chief Operating Officer effective as of April 15, 2021 but thereafter resigned effective as of April 28, 2021. Immediately after the consummation of the transaction and the issuance of the shares to the Investor, the Investor ownership in the Company is approximately 70.30% of the issued and outstanding shares of common stock of the Company. The foregoing description of the closing of the Ainos Agreement is not complete and is qualified in its entirety by the Form 8-K filed by the Company with the SEC on April 21, 2021, attached hereto as Exhibit 99.2 and which is incorporated herein by reference.

 

On April 27, 2021, the Company issued Note #12.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $15,000.  The Note is payable on October 27, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%.  The note has a maximum limit of $15,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity.  The Note may be convertible in whole or in part at a conversion price of $0.20 per share.

 

On April 28, 2021, Mr. Chia-Hsi Chen resigned as the Company’s Chief Operating Officer as of April 28, 2021 as reported by the Form 8-K filed by the Company with the SEC on May 3, 2021, attached hereto as Exhibit 99.3 and which is incorporated by reference.

 

On May 5, 2021, the Company issued Note #13.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $20,000.  The Note is payable on November 5, 2021, or on demand and bears interest at the Applicable Federal Rate (short-term rate) of 1.85%.  The note has a maximum limit of $20,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity.  The Note may be convertible in whole or in part at a conversion price of $0.20 per share.

 

Notes #11.21, #12.21, and #13.21 are un-secured and are due on demand.  All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933.  The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen and Ainos, Inc., a Cayman Islands Corporation are related party notes.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Convertible Notes Payable and Other Related Party Notes Payable (Tables)
3 Months Ended
Mar. 31, 2021
Notes Tables  
Convertible Debt
Note #.   Conversion Rate     Interest Rate     March 31, 2021     December 31, 2020  
Note 1 - Chen   $ 0.1680       0.75 %   $ 114,026     $ 114,026  
Note 2 - Chen   $ 0.1875       0.65 %   $ 262,500     $ 262,500  
Note 3.19 - Chen   $ 0.2500       1.85 %   $ 39,620     $ 39,620  
Note 4.19 - Chen   $ 0.2500       1.61 %   $ 14,879     $ 14,879  
Note 5.19 – i2China   $ 0.2500       1.85 %   $ 16,000     $ 16,000  
Note 6.20 - Chen   $ 0.2500       1.85 %   $ 216,600     $ 216,600  
Note 7.20 - Chen   $ 0.2500       1.60 %   $ 23,366     $ 23,366  
Note 8.20a – i2China   $ 0.2500       1.85 %   $ 48,000     $ 48,000  
Note 8.20b – i2China   $ 0.2500       1.85 %   $ 84,000     $ 84,000  
Note 9.21 - Chen     N/A       0.13 %   $ 236,854     $ 134,010  
Note 10.21 – Chen   $ 0.2500       1.85 %   $ 59,025       -  
Note 11 – i2China   $ 0.2500       1.85 %   $ 37,000       -  

 

Total Convertible Notes (including accrued Interest) – Related Party

 

  $ 1,151,870     $ 953,001              
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Common Stock (Details Narrative) - shares
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Stockholders' equity (deficit)    
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Stock issued during period 42,066,172  
Shares reserved for conversion of convertible debt to stock 4,032,919  
Stock issued as compensation 174,422  
Shares held for furutre exercise of noqualified options and warrants 5,109,617  
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Convertible Notes Payable - Related Party (Details Textual) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Convertible Notes Payable, Total $ 1,151,870 $ 953,001
Note 1    
Notes Payable, Convertible, Related Parties, Classified Current $ 114,026 114,026
Debt Instrument, Interest Rate, Stated Percentage 0.75%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.168  
Note 2    
Notes Payable, Convertible, Related Parties, Classified Current $ 262,500 262,500
Debt Instrument, Interest Rate, Stated Percentage 0.65%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.1875  
Note 3    
Notes Payable, Convertible, Related Parties, Classified Current $ 39,620 39,620
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 4    
Notes Payable, Convertible, Related Parties, Classified Current $ 14,879 14,879
Debt Instrument, Interest Rate, Stated Percentage 1.61%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 5    
Notes Payable, Convertible, Related Parties, Classified Current $ 16,000 16,000
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 6    
Notes Payable, Convertible, Related Parties, Classified Current $ 216,600 216,600
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 7    
Notes Payable, Convertible, Related Parties, Classified Current $ 23,366 23,366
Debt Instrument, Interest Rate, Stated Percentage 1.60%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 8a    
Notes Payable, Convertible, Related Parties, Classified Current $ 48,000 48,000
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 8b    
Notes Payable, Convertible, Related Parties, Classified Current $ 84,000 84,000
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 9    
Notes Payable, Convertible, Related Parties, Classified Current $ 236,854 134,010
Debt Instrument, Interest Rate, Stated Percentage 0.13%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0  
Note 10    
Notes Payable, Convertible, Related Parties, Classified Current $ 59,025 0
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
Note 11    
Notes Payable, Convertible, Related Parties, Classified Current $ 37,000 $ 0
Debt Instrument, Interest Rate, Stated Percentage 1.85%  
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 0.25  
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Convertible Notes Payable - Related Party - Convertible Notes Payable, Outstanding (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Convertible Notes Payable [Abstract]    
Convertible note payable $ 915,016 $ 953,001
EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 31 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 51 168 1 false 16 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://ainos.com/20200930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://ainos.com/20200930/role/statement-balance-sheets-current-period-unaudited Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://ainos.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://ainos.com/20200930/role/statement-statements-of-operations-unaudited Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://ainos.com/20200930/role/statement-statements-of-stockholders-equity-deficit-unaudited Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://ainos.com/20200930/role/statement-condensed-statements-of-cash-flows-unaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Note 1 - Organization and Business Sheet http://ainos.com/20200930/role/statement-note-1-organization-and-business Note 1 - Organization and Business Notes 7 false false R8.htm 00000008 - Disclosure - Note 2 - General Sheet http://ainos.com/20200930/role/statement-note-2 Note 2 - General Notes 8 false false R9.htm 00000009 - Disclosure - Note 3 - Basis of Presentation Sheet http://ainos.com/20200930/role/statement-note-3-basis-of-presentation Note 3 - Basis of Presentation Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 - Financial Condition Sheet http://ainos.com/20200930/role/statement-note-4-financial-condition Note 4 - Financial Condition Notes 10 false false R11.htm 00000011 - Disclosure - Note 5 - Common Stock Sheet http://ainos.com/20200930/role/statement-note-5-common-stock Note 5 - Common Stock Notes 11 false false R12.htm 00000012 - Disclosure - Note 6 - Convertible Notes Payable and Other Related Party Notes Payable Notes http://ainos.com/20200930/role/statement-note-6-convertible-notes-payable-related-party Note 6 - Convertible Notes Payable and Other Related Party Notes Payable Notes 12 false false R13.htm 00000013 - Disclosure - Note 7 - Other Related Party Transactions Sheet http://ainos.com/20200930/role/statement-note-7-other-related-party-transactions Note 7 - Other Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Note 8 - Subsequent Events Sheet http://ainos.com/20200930/role/statement-note-8-subsequent-events Note 8 - Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Note 6 - Convertible Notes Payable and Other Related Party Notes Payable (Tables) Notes http://ainos.com/20200930/role/statement-note-6-convertible-notes-payable-related-party-tables Note 6 - Convertible Notes Payable and Other Related Party Notes Payable (Tables) Tables http://ainos.com/20200930/role/statement-note-6-convertible-notes-payable-related-party 15 false false R16.htm 00000016 - Disclosure - Note 5 - Common Stock (Details Narrative) Sheet http://ainos.com/role/Note5-CommonStockDetailsNarrative Note 5 - Common Stock (Details Narrative) Details http://ainos.com/20200930/role/statement-note-5-common-stock 16 false false R17.htm 00000017 - Disclosure - Note 6 - Convertible Notes Payable - Related Party (Details Textual) Notes http://ainos.com/20200930/role/statement-note-6-convertible-notes-payable-related-party-details-textual Note 6 - Convertible Notes Payable - Related Party (Details Textual) Details 17 false false R18.htm 00000018 - Disclosure - Note 6 - Convertible Notes Payable - Related Party - Convertible Notes Payable, Outstanding (Details) Notes http://ainos.com/20200930/role/statement-note-6-convertible-notes-payable-related-party-convertible-notes-payable-outstanding-details Note 6 - Convertible Notes Payable - Related Party - Convertible Notes Payable, Outstanding (Details) Details 18 false false All Reports Book All Reports amar-20210331.xml amar-20210331.xsd amar-20210331_cal.xml amar-20210331_def.xml amar-20210331_lab.xml amar-20210331_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 36 0001654954-21-005724-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-21-005724-xbrl.zip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end